Huang Tsi-Shu, Lee Susan Shin-Jung, Hsueh Po-Ren, Tsai Hung-Chin, Chen Yao-Shen, Wann Shue-Ren, Leu Hsieh-Shong, Ko Wen-Chien, Yan Jing-Jou, Yuan Shi-Zhi, Chang Feng-Yee, Lu Jang-Jih, Wang Jen-Hsien, Wang Hua-Kung, Liu Yung-Ching
Section of Infectious Diseases and Microbiology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
J Formos Med Assoc. 2008 Apr;107(4):281-7. doi: 10.1016/s0929-6646(08)60088-1.
BACKGROUND/PURPOSE: To understand the resistance patterns of rapidly growing mycobacteria (RGM) in Taiwan, antimicrobial resistance of clinical isolates was determined as part of the SMART (Surveillance from Multicenter Antimicrobial Resistance in Taiwan) program.
During the period from January 2002 to December 2003, clinical isolates were collected from eight hospitals located on the west side of Taiwan and one reference laboratory. Broth microdilution minimum inhibitory concentrations of 11 antimicrobial agents were determined for 312 clinical isolates of RGM, including the Mycobacterium fortuitum group (110 isolates), Mycobacterium abscessus group (168 isolates), and Mycobacterium chelonae group (34 isolates).
Nearly all of the RGM were susceptible to amikacin and ofloxacin (= 90%) and resistant to doxycycline (less than 3% susceptible). Tobramycin showed similar in vitro activity against the M. fortuitum and M. chelonae (77%) groups, but was less active against the M. abscessus group (58%). Ciprofloxacin was active mainly against M. fortuitum (95%). Nearly all RGM were resistant to erythromycin and doxycycline. However, around half of the RGM isolates remained susceptible to minocycline (50-54%). Clarithromycin was active against the M. abscessus group (53% susceptible), with a high rate of resistance in the M. chelonae (38% susceptible) and M. fortuitum (15% susceptible) group. Cefoxitin was more active against the M. fortuitum group (65%) than the other two RGM (40-44%), and les than 40% of the RGM isolates remained susceptible to imipenem (21-38%).
The resistance of RGM in Taiwan is not as high as previously reported (notably for tobramycin, ciprofloxacin and cefoxitin), but reduction in the susceptibility rates of clarithromycin and imipenem for the M. fortuitum and M. abscessus groups demonstrates the importance of in vitro susceptibility testing of clinically important isolates, as susceptibility may differ in different geographical areas, even regionally, and over time.
背景/目的:为了解台湾快速生长分枝杆菌(RGM)的耐药模式,作为台湾多中心抗菌药物耐药监测(SMART)项目的一部分,对临床分离株的抗菌药物耐药性进行了测定。
在2002年1月至2003年12月期间,从台湾西部的八家医院和一个参考实验室收集临床分离株。对312株RGM临床分离株测定了11种抗菌药物的肉汤微量稀释最低抑菌浓度,其中包括偶然分枝杆菌组(110株)、脓肿分枝杆菌组(168株)和龟分枝杆菌组(34株)。
几乎所有RGM对阿米卡星和氧氟沙星敏感(=90%),对多西环素耐药(敏感率低于3%)。妥布霉素对偶然分枝杆菌和龟分枝杆菌组显示出相似的体外活性(敏感率77%),但对脓肿分枝杆菌组活性较低(敏感率58%)。环丙沙星主要对偶然分枝杆菌有活性(敏感率95%)。几乎所有RGM对红霉素和多西环素耐药。然而,约一半的RGM分离株对米诺环素仍敏感(敏感率50 - 54%)。克拉霉素对脓肿分枝杆菌组有活性(敏感率53%),在龟分枝杆菌组(敏感率38%)和偶然分枝杆菌组(敏感率15%)耐药率较高。头孢西丁对偶然分枝杆菌组(敏感率65%)的活性高于其他两种RGM(敏感率40 - 44%),且低于40%的RGM分离株对亚胺培南仍敏感(敏感率21 - 38%)。
台湾RGM的耐药性不像先前报道的那么高(尤其是妥布霉素、环丙沙星和头孢西丁),但克拉霉素和亚胺培南对偶然分枝杆菌和脓肿分枝杆菌组的敏感率下降表明,对临床重要分离株进行体外药敏试验很重要,因为药敏情况在不同地理区域甚至地区内以及随时间可能有所不同。